Arginine supplement with chemo and immunotherapy for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies whether adding an arginine supplement (a protein building block) to standard chemotherapy and immunotherapy can help treat platinum-resistant ovarian, fallopian tube, or peritoneal cancer. It might help the body's immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to be reasonably active and able to take care of yourself (performance status 0 or 1).
- Your cancer must be a type called 'high-grade serous' or 'high-grade endometrioid'.
- Your cancer must be 'platinum-resistant', meaning it doesn't respond well to platinum chemotherapy.
- If you are in one treatment group, a lab test (PD-L1) must show a certain level. In the other group, your PD-L1 level does not matter.
- You must have recovered from previous treatment side effects and have adequate blood, liver, and kidney function.
- You must be willing to take arginine (an amino acid) either by mouth or through an IV every day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
This trial tests a new combination of drugs given before surgery to shrink advanced ovarian cancer, which may make it easier to remove and improve outcomes. It includes an immunotherapy drug that helps your immune system fight cancer, along with standard chemotherapy.
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
This trial tests whether adding losartan, a blood pressure medication, to the chemotherapy drug paclitaxel can help treat ovarian cancer that has returned after platinum-based treatment. The goal is to see if this combination can slow or stop the cancer's growth.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.